A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

James B. Bussel, George R. Buchanan, Diane J. Nugent, David J. Gnarra, Lisa R. Bomgaars, Victor S. Blanchette, Yow Ming Wang, Kun Nie, Susie Jun

Research output: Contribution to journalArticle

136 Citations (Scopus)

Abstract

Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in children, patients with ITP of ≥ 6 months' duration were stratified by age 1:2:2 (12 months-< 3 years; 3-< 12 years; 12-< 18 years). Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 weeks, with dose adjustments to maintain platelet counts between 50 × 109/L and 250 × 10 9/L. A platelet count ≥ 50 × 109/L for 2 consecutive weeks was achieved by 15/17 (88%) patients in the romiplostim group and no patients in the placebo group (P = .0008). Platelet counts ≥ 50 × 109/L were maintained for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patients (P = .0019). The median weekly dose of romiplostim at 12 weeks was 5 μg/kg. Fourteen responders received romiplostim for 4 additional weeks for assessment of pharmacokinetics. No patients discontinued the study. There were no treatment-related, serious adverse events. The most commonly reported adverse events in children, as in adults, were headache and epistaxis. In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203.

Original languageEnglish (US)
Pages (from-to)28-36
Number of pages9
JournalBlood
Volume118
Issue number1
DOIs
StatePublished - Jul 7 2011

Fingerprint

Idiopathic Thrombocytopenic Purpura
Double-Blind Method
Platelets
Platelet Count
Safety
Placebos
Thrombopoietin
Epistaxis
Pharmacokinetics
Subcutaneous Injections
romiplostim
Headache

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Bussel, J. B., Buchanan, G. R., Nugent, D. J., Gnarra, D. J., Bomgaars, L. R., Blanchette, V. S., ... Jun, S. (2011). A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood, 118(1), 28-36. https://doi.org/10.1182/blood-2010-10-313908

A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. / Bussel, James B.; Buchanan, George R.; Nugent, Diane J.; Gnarra, David J.; Bomgaars, Lisa R.; Blanchette, Victor S.; Wang, Yow Ming; Nie, Kun; Jun, Susie.

In: Blood, Vol. 118, No. 1, 07.07.2011, p. 28-36.

Research output: Contribution to journalArticle

Bussel, JB, Buchanan, GR, Nugent, DJ, Gnarra, DJ, Bomgaars, LR, Blanchette, VS, Wang, YM, Nie, K & Jun, S 2011, 'A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia', Blood, vol. 118, no. 1, pp. 28-36. https://doi.org/10.1182/blood-2010-10-313908
Bussel, James B. ; Buchanan, George R. ; Nugent, Diane J. ; Gnarra, David J. ; Bomgaars, Lisa R. ; Blanchette, Victor S. ; Wang, Yow Ming ; Nie, Kun ; Jun, Susie. / A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. In: Blood. 2011 ; Vol. 118, No. 1. pp. 28-36.
@article{55ede58d97e648d5ba1bbbe503f3f5a3,
title = "A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia",
abstract = "Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in children, patients with ITP of ≥ 6 months' duration were stratified by age 1:2:2 (12 months-< 3 years; 3-< 12 years; 12-< 18 years). Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 weeks, with dose adjustments to maintain platelet counts between 50 × 109/L and 250 × 10 9/L. A platelet count ≥ 50 × 109/L for 2 consecutive weeks was achieved by 15/17 (88{\%}) patients in the romiplostim group and no patients in the placebo group (P = .0008). Platelet counts ≥ 50 × 109/L were maintained for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patients (P = .0019). The median weekly dose of romiplostim at 12 weeks was 5 μg/kg. Fourteen responders received romiplostim for 4 additional weeks for assessment of pharmacokinetics. No patients discontinued the study. There were no treatment-related, serious adverse events. The most commonly reported adverse events in children, as in adults, were headache and epistaxis. In this short-term study, romiplostim increased platelet counts in 88{\%} of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203.",
author = "Bussel, {James B.} and Buchanan, {George R.} and Nugent, {Diane J.} and Gnarra, {David J.} and Bomgaars, {Lisa R.} and Blanchette, {Victor S.} and Wang, {Yow Ming} and Kun Nie and Susie Jun",
year = "2011",
month = "7",
day = "7",
doi = "10.1182/blood-2010-10-313908",
language = "English (US)",
volume = "118",
pages = "28--36",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia

AU - Bussel, James B.

AU - Buchanan, George R.

AU - Nugent, Diane J.

AU - Gnarra, David J.

AU - Bomgaars, Lisa R.

AU - Blanchette, Victor S.

AU - Wang, Yow Ming

AU - Nie, Kun

AU - Jun, Susie

PY - 2011/7/7

Y1 - 2011/7/7

N2 - Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in children, patients with ITP of ≥ 6 months' duration were stratified by age 1:2:2 (12 months-< 3 years; 3-< 12 years; 12-< 18 years). Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 weeks, with dose adjustments to maintain platelet counts between 50 × 109/L and 250 × 10 9/L. A platelet count ≥ 50 × 109/L for 2 consecutive weeks was achieved by 15/17 (88%) patients in the romiplostim group and no patients in the placebo group (P = .0008). Platelet counts ≥ 50 × 109/L were maintained for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patients (P = .0019). The median weekly dose of romiplostim at 12 weeks was 5 μg/kg. Fourteen responders received romiplostim for 4 additional weeks for assessment of pharmacokinetics. No patients discontinued the study. There were no treatment-related, serious adverse events. The most commonly reported adverse events in children, as in adults, were headache and epistaxis. In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203.

AB - Romiplostim, a thrombopoietin-mimetic peptibody, increases and maintains platelet counts in adults with immune thrombocytopenia (ITP). In this first study of a thrombopoietic agent in children, patients with ITP of ≥ 6 months' duration were stratified by age 1:2:2 (12 months-< 3 years; 3-< 12 years; 12-< 18 years). Children received subcutaneous injections of romiplostim (n = 17) or placebo (n = 5) weekly for 12 weeks, with dose adjustments to maintain platelet counts between 50 × 109/L and 250 × 10 9/L. A platelet count ≥ 50 × 109/L for 2 consecutive weeks was achieved by 15/17 (88%) patients in the romiplostim group and no patients in the placebo group (P = .0008). Platelet counts ≥ 50 × 109/L were maintained for a median of 7 (range, 0-11) weeks in romiplostim patients and 0 (0-0) weeks in placebo patients (P = .0019). The median weekly dose of romiplostim at 12 weeks was 5 μg/kg. Fourteen responders received romiplostim for 4 additional weeks for assessment of pharmacokinetics. No patients discontinued the study. There were no treatment-related, serious adverse events. The most commonly reported adverse events in children, as in adults, were headache and epistaxis. In this short-term study, romiplostim increased platelet counts in 88% of children with ITP and was well-tolerated and apparently safe. The trial was registered with http://www.clinicaltrials.gov as NCT00515203.

UR - http://www.scopus.com/inward/record.url?scp=79960114674&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79960114674&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-10-313908

DO - 10.1182/blood-2010-10-313908

M3 - Article

C2 - 21502541

AN - SCOPUS:79960114674

VL - 118

SP - 28

EP - 36

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -